A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT06819878
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Moderately to Severely Active Crohns Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Afimkibart — DRUGAfimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
- Placebo — DRUGPlacebo matching IV afimkibart. Placebo matching SC afimkibart.
Study Details
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Key Dates
- First listed
- Feb 11, 2025
- Start date
- Mar 17, 2025
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2033
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1: AfimkibartParticipants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.
- Experimental: Arm 2: AfimkibartParticipants will receive afimkibart IV followed by afimkibart SC injection.
- Placebo Comparator: Arm 3: PlaceboParticipants will receive placebo IV followed by placebo SC.
Primary Outcome Measure
Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI) Score [ Time Frame: At Week 52 ]
Central Contacts
- Reference Study ID Number: GA45331 https://forpatients.roche.com/ No attachments to email below.888-662-6728 (U.S. and Canada)
- Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Locations (94)
Find similar trials in Dothan, AL
By research site
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan· Dothan, ALMayo Clinic Hospital· Phoenix, AZArizona Digestive Health, P.C (ADH)· Sun City, AZUniversity of Arizona-CATS Research Center· Tucson, AZValley View Internal Medicine· Garden Grove, CA310 Clinical Research· Inglewood, CA
Related Studies
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · Recruiting · Hoffmann-La Roche · Dothan, Alabama
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseasePHASE3 · Recruiting · Hoffmann-La Roche · New York, New York